Modern electroconvulsive therapy (ECT) and the approval of nasal esketamine for clinical
use have significantly improved the approach to treatment-resistant depression (TRD) …

This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …

About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …

Objective Treatment Resistant Depression (TRD) is commonly defined as the lack of
response to two or more antidepressants with different mechanisms of action. Up to 30% of …

Abstract Treatment-resistant depression (TRD) is a major public health problem worldwide.
There are currently five strategies for its treatment: optimization, change, combination …

Objectives Despite the available therapies for treatment-resistant depression (TRD), there
are a limited number that are evidence-based and effective in this hard-to-treat population …

The motive of this article is to review the pharmacological and clinical aspects of esketamine
(ESK), an NMDA-receptor antagonist approved recently by the FDA for treatment-resistant …

Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

Summary Background. Major Depressive Disorder represents a global burden disease with
highly heterogenous clinical features. Approximately 30-50% of patients do not respond to …

Treatment-resistant depression (TRD) is a problematic and prevalent public health and
societal concern. Although electroconvulsive therapy (ECT) is the gold standard TRD …